Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
AxoGen (DE:LT3)
FRANKFURT:LT3
Holding DE:LT3?
Track your performance easily
LT3 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€4.66 - €14.30
Previous Close€13
Volume0.00
Average Volume (3M)283.00
Market Cap
€549.56M
Enterprise Value€570.92M
Total Cash (Recent Filing)$24.53M
Total Debt (Recent Filing)$47.27M
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Mar 04, 2025EPS Estimate
€0.02Last Dividend Ex-Date
Jan 27, 2010Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding44,008,259
10 Day Avg. Volume0
30 Day Avg. Volume283
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)5.75
Price to Sales (P/S)3.40
Price to Cash Flow (P/CF)39.40
P/FCF Ratio55.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.16
Enterprise Value/Gross Profit4.46
Enterprise Value/Ebitda-337.03
Forecast
1Y Price Target
€17.17Price Target Upside32.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
AxoGen News
PremiumCompany Announcements
Axogen Reports Strong Q3 Growth and FDA Progress
PremiumCompany Announcements
AxoGen Reports Strong Q3 2024 Revenue Growth
Bulls Say, Bears Say
Bulls Say
EarningsAXGN posted solid Q3 results, beating top- and bottom-line expectations.
Growth StrategyAxoGen has truly differentiated products for nerve protection and repair, facing limited biologic competition, which presents ample growth opportunities.
Product ApprovalFDA approval of Avance in 2025 is considered less risky after the agency accepted the BLA submission.
Bears Say
Financial PerformanceManagement lowered FY24 gross margin to approximately 74-76%, which is below the previous estimate.
Market ReactionThe management's reiteration of full-year guidance was seen as overly conservative, contributing to an unwarranted sell-off.
Regulatory ChallengesThe FDA did not grant AXGN's request for priority review, resulting in a later decision date.
---
Options Prices
Currently, No data available
---
Ownership Overview
5.55% Insiders
18.05% Mutual Funds
8.08% Other Institutional Investors
54.34% Public Companies and
Individual Investors
LT3 FAQ
What was AxoGen’s price range in the past 12 months?
AxoGen lowest stock price was €4.66 and its highest was €14.30 in the past 12 months.
What is AxoGen’s market cap?
Currently, no data Available
When is AxoGen’s upcoming earnings report date?
AxoGen’s upcoming earnings report date is Mar 04, 2025 which is in 110 days.
How were AxoGen’s earnings last quarter?
AxoGen released its earnings results on Nov 07, 2024. The company reported €0.066 earnings per share for the quarter, beating the consensus estimate of €0.006 by €0.06.
Is AxoGen overvalued?
According to Wall Street analysts AxoGen’s price is currently Undervalued.
Does AxoGen pay dividends?
AxoGen pays a Notavailable dividend of €0.94 which represents an annual dividend yield of N/A. See more information on AxoGen dividends here
What is AxoGen’s EPS estimate?
AxoGen’s EPS estimate is €0.02.
How many shares outstanding does AxoGen have?
AxoGen has 44,008,260 shares outstanding.
What happened to AxoGen’s price movement after its last earnings report?
AxoGen reported an EPS of €0.066 in its last earnings report, beating expectations of €0.006. Following the earnings report the stock price went down -1.399%.
Which hedge fund is a major shareholder of AxoGen?
Among the largest hedge funds holding AxoGen’s share is Perceptive Advisors LLC. It holds AxoGen’s shares valued at 220K.
---
AxoGen Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€17.17 (32.11% Upside)
€17.17 (32.11% Upside)
Blogger Sentiment
Bullish
DE:LT3 Sentiment 100%
Sector Average 72%
Sector Average 72%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
164.34%
12-Months-Change
Fundamentals
Return on Equity
-14.51%
Trailing 12-Months
Asset Growth
-1.36%
Trailing 12-Months
Company Description
AxoGen
AxoGen, Inc. engages in the development and market of surgical solutions for peripheral nerves. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. Its products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.
---
LT3 Company Deck
---
LT3 Earnings Call
Q3 2024
0:00 / 0:00
---
LT3 Stock 12 Month Forecast
Average Price Target
€17.17
▲(32.11% Upside)
Technical Analysis
AxoGen
―
TransMedics Group
―
Fate Therapeutics
―
Axsome Therapeutics
―
Kala Pharmaceuticals
―
Best Analysts Covering LT3
1 Year
1 Year Success Rate
12/23 ratings generated profit
1 Year Average Return
+24.13%
reiterated a buy rating 6 days ago
Copying David Turkaly's trades and holding each position for 1 Year would result in 52.17% of your transactions generating a profit, with an average return of +24.13% per trade.
---